Twin Tree Management, LP Neurocrine Biosciences Inc Put Options Transaction History

Twin Tree Management, LP

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $12.6 Million - $16.9 Million	110,200 Added 781.56%	124,300 $14.3 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $1.85 Million - $2.02 Million	14,100 New	14,100 $1.94 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $1.68 Million - $2.29 Million	19,200 Added 117.79%	35,500 $3.45 Million
Q3 2019 Nov 12, 2019	BUY	$83.82 - $101.5 $947,165 - $1.15 Million	11,300 Added 226.0%	16,300 $1.47 Million
Q1 2019 May 10, 2019	SELL	$69.31 - $91.53 $291,102 - $384,426	-4,200 Reduced 45.65%	5,000 $440,000
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $628,543 - $1.14 Million	9,200 New	9,200 $657,000

634

94.1M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

Stay updated on Twin Tree Management, LP with notifications on news.